Cannabidiol Medication Intervention Trial (CALM-IT)

Summary

Agitation is common in patients with Alzheimer's Disease (AD) and is one of the most distressing and symptoms of AD. Agitation is associated with faster loss of independent living, increased caregiver stress, poorer quality of life, and increased risk of death. In addition, current treatments show only mild benefits but come with side effects. Therefore, identifying safer and more effective treatments for agitation in AD is a priority.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 55 to 100

Inclusion criteria:

1. Diagnosis of Alzheimer's disease
2. Significant agitation
3. 55 years or older
4. Availability of a caregiver that can participate along with the participant

Exclusion criteria:

1. Allergies to cannabis and cannabis products.
2. Presence of significant delusions and/or hallucinations.
3. Major depression.

Participate

Fill out the following form if you want to participate in this research

Method of contact

UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is committed to ensuring the privacy of all students, staff, and community members. Your personal information is being collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used and disclosed for the purposes outlined in UCalgary’s Notice of Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s Privacy Management Program. Your personal information may be input into automated systems to generate content or make decisions, recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection, use, or disclosure of your personal information, please contact accessandprivacy@ucalgary.ca.

Additional information

Contact information

Ramnik Sekhon

Principal investigator:

Zahinoor Ismail

Clinical trial:

Yes

REB-ID:

REB24-0702